

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

November 13, 2023

Richard Rychlik VP, Corporate Controller Armata Pharmaceuticals, Inc. 5005 McConnell Avenue Los Angeles, CA 90066

Re: Armata Pharmaceuticals, Inc.

Form 10-K for the fiscal year ended December 31, 2022 Form 10-Q for the quarterly period ended June 30, 2023

File No. 001-37544

Dear Richard Rychlik:

We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance Office of Life Sciences